Straight Path Wealth Management - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
Straight Path Wealth Management ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$19,116
-16.3%
16,2000.0%0.01%
-18.8%
Q2 2023$22,842
-6.0%
16,2000.0%0.02%
-15.8%
Q1 2023$24,300
+28.2%
16,2000.0%0.02%
+5.6%
Q4 2022$18,954
+5.3%
16,2000.0%0.02%
+12.5%
Q3 2022$18,000
-30.8%
16,2000.0%0.02%
-36.0%
Q2 2022$26,000
+4.0%
16,2000.0%0.02%
+19.0%
Q1 2022$25,000
-37.5%
16,2000.0%0.02%
-40.0%
Q4 2021$40,00016,2000.04%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$83,313,0005.12%
Defender Capital, LLC. 4,997,870$12,245,0003.92%
Raffles Associates 543,590$1,332,0001.28%
Prescott General Partners LLC 1,851,851$4,537,0000.16%
DCF Advisers, LLC 85,000$208,0000.08%
Long Focus Capital Management, LLC 215,000$527,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$110,0000.06%
DAFNA Capital Management LLC 80,000$196,0000.05%
Strategic Wealth Investment Group, LLC 65,069$159,0000.04%
Fort Sheridan Advisors LLC 52,931$130,0000.04%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders